BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 33734974)

  • 1. Protective effect of different doses of trimethoprim-sulfamethoxazole prophylaxis for early severe infections among patients with antineutrophil cytoplasmic autoantibody-associated vasculitis.
    Waki D; Nishimura K; Yoshida T; Tanaka N; Mizukawa K; Fukushima M; Iri O; Anegawa M; Murabe H; Yokota T
    Clin Exp Rheumatol; 2021; 39 Suppl 129(2):142-148. PubMed ID: 33734974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy evaluation of low-dose trimethoprim-sulfamethoxazole for prophylaxis of Pneumocystis pneumonia in HIV uninfected patients undergoing hemodialysis: a retrospective observational study.
    Yamashita K; Shimomura Y; Ikesue H; Muroi N; Yoshimoto A; Hashida T
    BMC Infect Dis; 2021 Jul; 21(1):664. PubMed ID: 34238239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of trimethoprim/sulfametoxazole in reducing relapses and risk of infections in ANCA-associated vasculitis: a meta-analysis.
    Monti S; Delvino P; Riboli M; Rebuffi C; Xoxi B; De Silvestri A; Montecucco C
    Rheumatology (Oxford); 2021 Aug; 60(8):3553-3564. PubMed ID: 33752235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trimethoprim-sulfamethoxazole prophylaxis during treatment of granulomatosis with polyangiitis with rituximab in the United States of America: a retrospective cohort study.
    Mendel A; Behlouli H; de Moura CS; Vinet É; Curtis JR; Bernatsky S
    Arthritis Res Ther; 2023 Jul; 25(1):133. PubMed ID: 37516897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trimethoprim-Sulfamethoxazole-associated early neutropenia in Mexican adults living with HIV: A cohort study.
    Jacobo-Vargas TB; Báez-Saldaña R; Cruz-Hervert LP; Fortoul TI; Ahumada-Topete VH; Rodríguez-Ganén O; Vega-Barrientos RS
    PLoS One; 2023; 18(5):e0285541. PubMed ID: 37167312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High daily doses of trimethoprim/sulfamethoxazole are an independent risk factor for adverse reactions in patients with pneumocystis pneumonia and AIDS.
    Chang HM; Tsai HC; Lee SS; Kunin C; Lin PC; Wann SR; Chen YS
    J Chin Med Assoc; 2016 Jun; 79(6):314-9. PubMed ID: 27025225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary Prophylaxis for Pneumocystis jirovecii Pneumonia in Patients Receiving Rituximab.
    Park JW; Curtis JR; Jun KI; Kim TM; Heo DS; Ha J; Suh KS; Lee KW; Lee H; Yang J; Kim MJ; Choi Y; Lee EB
    Chest; 2022 May; 161(5):1201-1210. PubMed ID: 34788668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk factors associated with increased discontinuation rate of trimethoprim-sulfamethoxazole used as a primary prophylaxis for Pneumocystis pneumonia: A retrospective cohort study.
    Otani T; Yamaguchi K; Sakamoto S; Horimasu Y; Masuda T; Miyamoto S; Nakashima T; Iwamoto H; Hirata S; Fujitaka K; Hamada H; Sugiyama E; Hattori N
    Pulm Pharmacol Ther; 2021 Apr; 67():101999. PubMed ID: 33571651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Higher risk of urinary tract infections in renal transplant recipients receiving pentamidine versus trimethoprim-sulfamethoxazole (TMP-SMX) for Pneumocystis pneumonia prophylaxis.
    Fu W; Barahona M; Harkness T; Cohen E; Reardon D; Yoo PS
    Clin Transplant; 2020 Nov; 34(11):e14067. PubMed ID: 32810885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful prophylaxis against Pneumocystis carinii pneumonia in HIV-infected children using smaller than recommended dosages of trimethoprim-sulfamethoxazole.
    Fisher RG; Nageswaran S; Valentine ME; McKinney RE
    AIDS Patient Care STDS; 2001 May; 15(5):263-9. PubMed ID: 11530767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pneumocystis pneumonia in patients with rheumatic diseases receiving prolonged, non-high-dose steroids-clinical implication of primary prophylaxis using trimethoprim-sulfamethoxazole.
    Park JW; Curtis JR; Kim MJ; Lee H; Song YW; Lee EB
    Arthritis Res Ther; 2019 Sep; 21(1):207. PubMed ID: 31521185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trimethoprim-sulfamethoxazole significantly reduces the risk of nocardiosis in solid organ transplant recipients: systematic review and individual patient data meta-analysis.
    Passerini M; Nayfeh T; Yetmar ZA; Coussement J; Goodlet KJ; Lebeaux D; Gori A; Mahmood M; Temesgen Z; Murad MH
    Clin Microbiol Infect; 2024 Feb; 30(2):170-177. PubMed ID: 37865337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trimethoprim-Sulfamethoxazole for Pediatric Osteoarticular Infections.
    McDaniel LM; Fiawoo S; Tamma PD; Same RG
    J Pediatric Infect Dis Soc; 2023 Oct; 12(10):534-539. PubMed ID: 37757866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduction of
    Honda N; Tagashira Y; Kawai S; Kobayashi T; Yamamoto M; Shimada K; Yokogawa N
    Scand J Rheumatol; 2021 Sep; 50(5):365-371. PubMed ID: 33749507
    [No Abstract]   [Full Text] [Related]  

  • 15. Adverse effects of trimethoprim-sulfamethoxazole for the prophylaxis of Pneumocystis pneumonia in dermatology.
    Kokubu H; Kato T; Nishikawa J; Tanaka T; Fujimoto N
    J Dermatol; 2021 Apr; 48(4):542-546. PubMed ID: 33492693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of the concomitant use of methotrexate and a prophylactic dose of trimethoprim-sulfamethoxazole.
    Kwon OC; Lee JS; Kim YG; Lee CK; Yoo B; Hong S
    Clin Rheumatol; 2018 Dec; 37(12):3215-3220. PubMed ID: 29383453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between different infection profiles and one-year outcomes in ANCA-associated vasculitis: a retrospective study with monthly infection screening.
    Xu T; Chen Z; Jiang M; Ma H; Jin K; Wang Z; Wang C; Xu J; Zhang W
    RMD Open; 2022 Oct; 8(2):. PubMed ID: 36270741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors for serious infections in ANCA-associated vasculitis.
    Odler B; Riedl R; Gauckler P; Shin JI; Leierer J; Merkel PA; St Clair W; Fervenza F; Geetha D; Monach P; Jayne D; Smith RM; Rosenkranz A; Specks U; Stone JH; Kronbichler A;
    Ann Rheum Dis; 2023 May; 82(5):681-687. PubMed ID: 36702528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of prophylaxis for Pneumocystis jirovecii pneumonia involving trimethoprim-sulfamethoxazole dose reduction in kidney transplantation.
    Prasad GVR; Beckley J; Mathur M; Gunasekaran M; Nash MM; Rapi L; Huang M; Zaltzman JS
    BMC Infect Dis; 2019 Apr; 19(1):311. PubMed ID: 30953458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multicenter study of trimethoprim/sulfamethoxazole-related hepatotoxicity: incidence and associated factors among HIV-infected patients treated for Pneumocystis jirovecii pneumonia.
    Yang JJ; Huang CH; Liu CE; Tang HJ; Yang CJ; Lee YC; Lee KY; Tsai MS; Lin SW; Chen YH; Lu PL; Hung CC
    PLoS One; 2014; 9(9):e106141. PubMed ID: 25184238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.